NASDAQ: ALDX

Aldeyra Therapeutics, Inc.

Healthcare | Biotechnology

No licensed closing price on file for ALDX. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 09:46 UTC.

What Aldeyra Therapeutics, Inc. does

Aldeyra Therapeutics is a biotechnology company developing pharmaceuticals to treat immune-mediated diseases by modulating protein systems rather than targeting single proteins. The company's product candidates include RASP modulators and other compounds in development for conditions such as dry eye disease, allergic conjunctivitis, and retinal diseases. In a significant partnership arrangement, AbbVie has an exclusive option to license reproxalap, one of the company's late-stage candidates, with potential milestone payments and profit-sharing if the option is exercised.

Summarized from Aldeyra Therapeutics, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Key facts

Charts

Charts are in the appInteractive charts for ALDX are available in Oxford Ledge.
Open ALDX in Oxford Ledge →

SEC Filings

SEC EDGAR ↗

Recent Insider Activity

Source: SEC EDGAR · Filed 2026-06-11

Most recent filed transactions — June 2026:

2026-06-11DirectorStock Option (Right to Buy)Award3,318—
2026-06-11DirectorStock Option (Right to Buy)Award4,977—
2026-06-11DirectorStock Option (Right to Buy)Award4,977—

Top Institutional Holders (latest 13F)

Source: SEC EDGAR · As of 2026-Q2

Knoll Capital Management, LLC5,475,516$11.66M0.0%
AQR CAPITAL MANAGEMENT LLC3,751,558$7.99M+34.9%
KINGDON CAPITAL MANAGEMENT, L.L.C.2,652,315$5.65M+23.2%

View QoQ ownership changes →Full institutional ownership →

Recent 8-K Events (parsed from SEC filings)All events →

Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

2026-04-20Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →
2024-09-03Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →
2022-04-28Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →

Company news

View all →

Aldeyra Therapeutics, Inc. (ALDX) Discusses FDRR and FDA Review Process for Reproxalap in Dry Eye Disease - Slideshow
Seeking Alpha Feed2026-09-30
Aldeyra Therapeutics to Host Regulatory Update Webcast
businesswire.com2026-09-28
Aldeyra Therapeutics: What Comes Next After Reproxalap's Third CRL
Seeking Alpha Feed2026-07-10
Aldeyra Therapeutics Appoints Darlene Deptula-Hicks to Board of Directors
businesswire.com2026-06-09
Aldeyra Therapeutics Eyes FDA Feedback as Dry Eye Drug Faces Make-or-Break Moment
marketbeat.com2026-06-04

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for ALDX and 5,000+ tickers.

Create a free account — keep ALDX

For your agent

GET /api/data?ticker=ALDX

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt